Redaktion

**2025: Spannende Neuerungen bei der Psoriasis-Behandlung** Das Jahr 2025 bringt große Fortschritte in der Psoriasis-Therapie.[1][2] Das Wichtigste: Ärzte definieren jetzt gemeinsam, was Remission bedeutet. Das ist eine Haut ohne Symptome, die mindestens 6 Monate anhält.[2] In der Pipeline sind besonders zwei Neuentwicklungen vielversprechend. Der TYK2-Inhibitor Deucravacitinib zeigt beeindruckende Langzeitergebnisse.[2] 70 Prozent der Patienten behalten ihren Behandlungserfolg über 5 Jahre.[2] Das Medikament ist oral und braucht keine regelmäßigen Bluttests. Noch spannender ist ein neues orales Peptid namens Icotrokinra.[2] In aktuellen Studien erreichten 65 Prozent der Patienten die höchste Verbesserungsstufe.[2] Eine Pille statt Spritze – das erleichtert vielen die Therapie. Auch andere Medikamente wurden neu zugelassen. Der IL-23-Inhibitor Guselkumab ist jetzt sogar für Kinder ab 6 Jahren genehmigt.[2] Das bedeutet: Immer mehr Menschen mit Psoriasis haben Optionen, die zu ihnen passen. Das Ziel der Ärzte hat sich verändert. Sie wollen nicht nur die Symptome lindern. Sie streben echte Remission an.[ Originaltitel: Major Developments in Psoriatic Disease Link zur Quelle

The user is asking me to write an article as a news portal editor for people with psoriasis or psoriatic arthritis. The instructions say: - Write in a loose but correct style - Write so a 10th grader can understand - Avoid complex sentences, max one comma per sentence - Avoid nominalization (Substantivierungen) - Create paragraphs when a thought is complete - Max 1000 characters The topic is: "Psoriasis Advances That Could Change Daily Practice - An IL-23 inhibitor with less frequent dosing, combinations with GLP-1 drugs, and more" Looking at the search results, I can find information about: 1. Icotrokinra - an oral IL-23 inhibitor that showed durable psoriasis control at 1 year 2. IL-23 inhibitors in general - their efficacy, how they work 3. High-impact areas with limited disease 4. Combinations mentioned but no detailed info in search results about GLP-1 drugs The user wants me to summarize these advances. The title mentions "combinations with GLP-1 drugs" but I don't see detailed information about this in the search results. I should acknowledge what I can cite and note that the GLP-1 combination information isn't clearly covered in the provided search results. Let me write an accessible German article for people with psoriasis: Key points to cover: - Icotrokinra - oral IL-23 inhibitor (from source [1]) - Benefits: like injectable but as a pill - Efficacy data: high clearance rates - Less frequent dosing: IL-23 inhibitors need less frequent dosing than IL-17 inhibitors (from source [3]) - High-impact areas: IL-23 inhibitors work well in these areas even with limited body surface area (from source [3]) I need to make this accessible, avoid long sentences, max 1000 characters. Let me write: --- Neue Therapien gegen Psoriasis Gute Nachrichten für Patienten mit Schuppenflechte: Es gibt neue Behandlungsmöglichkeiten. Eine wichtige Neuerung ist ein IL-23-Hemmer, den man als Tablette nehmen kann. Bisher brauchte man oft Spritzen. Diese neue Tablette wirkt genauso gut wie die Spritzen. Das ist ein großer Vorteil für viele Patienten. In einer großen Studie mit etwa 700 Patienten hat sich das gezeigt. Fast 90 Prozent der Patienten hatten eine deutliche Verbesserung ihrer Haut. Das Medikament muss man seltener nehmen als andere Biologika. Das macht die Behandlung im Alltag einfacher. Besonders bei schwer erreichbaren Stellen wie Handflächen oder Fußsohlen wirken die neuen Mittel sehr gut. Das hilft vielen Patienten, die vorher weniger Erfolg hatten. Insgesamt eröffnen sich damit neue Möglichkeiten für Menschen mit Schuppenflechte. Die neuen IL-23-Hemmer stellen einen bedeutenden Fortschritt dar: Sie vereinfachen die Behandlung von Schuppenflechte erheblich und zeigen dabei mindestens genauso gute Ergebnisse wie bisherige Therapien. Für viele Patienten bedeutet das eine spürbare Verbesserung ihrer Lebensqualität. Nach einem Jahr hatten fast 90 Prozent der Patienten eine vollständige Hautklärung erreicht, und 84 Prozent behielten diese Verbesserung langfristig[1]. Ein wesentlicher Vorteil liegt in der Dosierungshäufigkeit – diese neuen Medikamente erfordern weniger häufige Anwendungen, was den Alltag der Patienten erheblich vereinfacht[3]. Besonders beeindruckend ist ihre Wirksamkeit auch an schwierig zu behandelnden Stellen wie den Handflächen[3], was für Menschen mit schwerem Krankheitsverlauf einen großen Unterschied macht. Originaltitel: Psoriasis Advances That Could Change Daily Practice Link zur Quelle

IntroductionNail psoriasis is a common, treatment-refractory manifestation of psoriasis. Smoking is a key environmental factor implicated in nail and articular psoriasis. While smoking's association with cutaneous psoriasis is well-studied, its relationship with nail psoriasis remains less explored.ObjectiveThe primary objective of this study was to investigate the impact of smoking on the severity of nail psoriasis and arthritic psoriasis in patients with nail psoriasis.MethodsData from 1044 nail psoriasis patients within a population-based registry in China were analyzed. We assessed associations of smoking status and intensity with sociodemographics, disease severity and dermatology quality of life measures (including PASI, BSA, DLQI, and PEST scores), and PsA diagnosis. Analyses used SPSS 29.0; p < 0.05 defined significance.ResultsThe current smoking rate among patients with nail psoriasis is 34.6%, which is much higher than the current smoking rate among patients without nail psoriasis (20.2%). The proportions of the three different smoking intensities are also much higher than those among patients without nail psoriasis. Current smoking affects the total nail involvement count in patients with nail psoriasis, and severe smoking affects both the total nail involvement count and the nails with > 90% area involvement count in these patients. However, we found that smoking intensity was negatively correlated with DLQI scores in nail psoriasis, which is contrary to previous studies on plaque psoriasis. Spearman's correlation analysis revealed that smoking intensity and smoking index were positively associated with total nail involvement count and individual nails > 90% with area involvement count. In the regression analysis for PSA, the OR for current smokers was 0.57 (95% CI: 0.35-0.92) compared to non-smokers, and the OR for severe smokers was 0.37 (95% CI: 0.15-0.90) compared to mild smokers.ConclusionPatients with nail psoriasis have higher smoking rates and smoking intensity compared to those without nail psoriasis. The total nail involvement count was higher in current smokers than in non-smokers. Smoking intensity was positively associated with total nail involvement count and individual nails with > 90% area involvement count. Current smoking was a negative associated factor for PEST risk level. Both current smoking and severe smoking were negative associations with the presence of psoriatic arthritis.Weiterlesen

AimThe current work highlighted the preparation method of Tanshinone IIA, Glycyrrhetinic acid Emulsion with eutectic (GT-eEmu) and investigated its effectiveness in the internal and external treatment of psoriasis.Materials & methodsThe optimal prescription ratios of the emulsions were screened based on single-factor and orthogonal experiments, in which the appearance, particle size, centrifugal stability, and placement stability of the emulsion were used as indicators. On this basis, the maximum drugs loading was determined and optimized by D-optimal. Then the gloss, consistency, uniformity, spreading, and centrifugal stability of the emulsion gel were used as indicators to screen the best preparation method of the emulsion gel. The gastrointestinal stability of GT-eEmu and the original drug was evaulated by the artificial gastrointestinal fluid test, while the irritation to the the gastrointestinal mucosa was investigated after treatment. In addition, the skin permeability and skin side effects of the preparation were studied. Finally, the therapeutic effects of various preparations on psoriasis in mice were studied based on PASI scores, HE pathological sections and the expression of SOCS1 and STAT3.ResultsThe best optimized prescription of GT-eEmu was: oil phase 7%, emulsifier 4.5%, and emulsification temperature 60 ℃, where the drug loading of TSN IIA and GA were 0.17 and 0.70 g·L- 1. The best preparation method for GT-eEmu-Gel was to add carbomer 980 with 6% gel matrix to the emulsion prepared by the optimized method, followed by mixing with triethanolamine and adjusting the pH to 6.0-7.0 to prepare a 0.5% carbomer matrix emulsion. The gastrointestinal stability experiment showed that the addition of eutectic ingredients did not cause significant irritation to the gastrointestinal tract, while the good permeability and sustained release of GT-eEmu-Gel were shown by in vitro release assays and the emulsion gel form could further reduce the irritation of eutectic to the skin. Finally, imiquimod-induced psoriasis animal model experiments indicated that GT-eEmu and its gel could reduce the degree of skin lesions and histopathological changes in model mice, and decrease the average expression of SOCS1 and STAT3, which indicated these preparation had therapeutic effects on psoriasis. Additionally, the "internal and external treatment" group had the best effect compared with the oral-only group, while there was a significant difference (P < 0.01) compared with the model group.ConclusionThe preparation process of GT-eEmu and GT-eEmu-Gel is stable and quality-controlled, which can improve the oral bioavail ability of both drugs to different degrees and reduce the irritation to the skin. The results showed that they have certain therapeutic effects on psoriasi, which can be safely administered orally and applied externally on the skin. At the same time, compared with the single treatment, the "internal and external combined treatment" method was the most effective, which indicates the concept of "internal and external combined treatment" method has practical significance.Weiterlesen

PurposePsoriasis is frequently associated with dyslipidemia, yet the role of specific unsaturated fatty acid (UFA) metabolic pathways in disease pathogenesis and treatment response remains poorly understood. This study aimed to characterize the landscape of UFA metabolic reprogramming in psoriasis and evaluate its clinical relevance for predicting response to biologic therapy.Patients and methodsWe performed an integrated multi-omics analysis incorporating transcriptomic data from human psoriatic lesions, single-cell RNA sequencing, and lipidomic profiling. Gene set variation analysis (GSVA) was used to evaluate UFA pathway activity. Logistic regression and LASSO were employed for biomarker selection and predictive modeling.ResultsWe identified eight significantly dysregulated UFA metabolic pathways in psoriatic lesions, six of which were associated with key pathogenic processes in psoriasis. All pathways were reversibly modulated by biologic agents targeting TNF-α, IL-12/23, and IL-17A. We derived a three-gene biomarker signature (PLA2G4D, PLA2G4A, and FADS2) that robustly predicts response to IL-12/23 inhibition prior to treatment initiation (AUC = 0.902). Single-cell RNA sequencing revealed keratinocytes as the primary cellular contributors to UFA metabolism and identified an expanded PLA2G4D-high keratinocyte subpopulation in psoriatic skin, which was associated with the accumulation of Lysophosphatidylcholine (LysoPC) and Lysophosphatidylethanolamine (LysoPE).ConclusionOur findings elucidate the pathway-level metabolic basis of psoriasis inflammation and provide a clinically applicable tool for predicting response to biologic therapy. The results highlight the importance of UFA metabolic reprogramming in psoriatic pathogenesis and offer new avenues for treatment personalization.Weiterlesen

Psoriasis is a chronic, immune-mediated dermatological disorder characterized by keratinocyte hyperproliferation and persistent inflammation, representing a significant therapeutic challenge. Conventional topical therapies are often limited by inadequate skin penetration, poor drug stability, and systemic toxicity, necessitating the development of advanced drug delivery platforms. Recent progress in colloid and interface science has enabled the design of nanocarrier systems including solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and liposomes that optimize drug-skin interactions at the nanoscale. Through interface engineering, these carriers improve drug solubility, stability, and controlled release, while enhancing epidermal localization and minimizing off-target exposure. Lipid-based nanosystems, in particular, leverage the skin's lipid pathways to achieve higher drug accumulation in psoriatic lesions, thereby improving therapeutic outcomes and patient compliance. Preclinical and early clinical studies with drugs such as methotrexate and cyclosporine have demonstrated enhanced lesion resolution, reduced side effects, and superior safety profiles when delivered via nanocarriers. Nevertheless, the clinical translation of these systems is often hindered by challenges such as large-scale reproducibility, formulation stability, and regulatory complexity. Interface-engineered nanocarriers address these limitations by employing biocompatible materials, scalable synthesis techniques, and targeted design strategies that enhance safety, efficacy, and translational feasibility. This review integrates mechanistic insights from colloid and interface engineering with translational perspectives on formulation scalability, regulatory pathways, and long-term safety evaluation. Collectively, interface-tailored nanocarriers represent a transformative approach for precision-driven, effective, and patient-centered topical therapy of psoriasis.Weiterlesen

No abstract supplied.Weiterlesen

BackgroundPsoriasis is a chronic inflammatory skin disorder that has been increasingly linked to metabolic imbalances, particularly obesity. Conventional anthropometric indicators such as BMI and waist circumference (WC) may not sufficiently capture body fat distribution or reflect metabolic risk. The body roundness index (BRI), which integrates both height and waist measurements, has emerged as a potentially superior metric, though its relevance to psoriasis risk remains underexplored.ObjectiveThis study aimed to investigate the use of BRI as a digital biomarker for assessing psoriasis risk and to compare its predictive strength against BMI and WC across various demographic and metabolic subgroups using data from a nationally representative sample.MethodsA cross-sectional analysis was conducted using data from 13,798 adults aged 20 to 59 years who participated in the National Health and Nutrition Examination Survey between 2003 and 2006 as well as between 2009 and 2014. Psoriasis status was self-reported. Anthropometric measures (BRI, BMI, and WC) were calculated from standardized physical assessments. Weighted multivariable logistic regression models and restricted cubic spline analyses were used to examine associations while adjusting for demographic, metabolic, and lifestyle variables. A nomogram was constructed to quantify the relative predictive contributions of each metric.ResultsBRI exhibited a strong linear association with psoriasis risk (odds ratio [OR] 1.11 per unit increase, 95% CI 1.05-1.17; P<.001), outperforming BMI (OR 1.03) and WC (OR 1.01). Tertile analysis revealed a 1.73-fold increased risk of psoriasis in the highest BRI group (P=.003). Subgroup analyses confirmed consistent associations across age, sex, race or ethnicity, and metabolic status (P for interaction >.05). The nomogram highlighted BRI as the most influential predictor, indicated by its broad scoring range.ConclusionsBRI shows stronger and more consistent associations with psoriasis risk than BMI or WC, supporting its potential role as a digital biomarker for early risk stratification. Incorporating BRI into clinical decision-making tools may enhance personalized approaches to psoriasis prevention and management.Weiterlesen

No abstract supplied.Weiterlesen

BackgroundPsoriasis is a systemic disease that brings enormous mental pressure and economic burden to patients and has a significant impact on patients' quality of life (QoL). This study aimed to explore factors affecting the dermatology life quality index (DLQI) in patients with psoriasis.MethodsThis retrospective cross-sectional study used data sourced from the Psoriasis Diagnosis and Treatment Real-world Database, and 8839 patients with psoriasis (recruited between June 24, 2020 and September 2, 2021) were included. Demographic and clinical characteristics and DLQI scores were retrospectively analyzed, and correlations between DLQI score and age, disease course, psoriasis area and severity index (PASI) score were calculated. Regression analysis was conducted to explore the factors affecting the DLQI scores of patients with psoriasis.ResultsThe average DLQI scores were significantly higher in young (8.58 ± 7.22) and middle-aged individuals (8.09 ± 6.61) than those in juveniles (6.00 ± 5.79) and older individuals (7.39 ± 6.29) (P = 1.70E-15). The average DLQI scores gradually decreased among individuals whose work status were unemployment (10.4 ± 7.83), part-time (9.02 ± 6.83), full-time (8.43 ± 6.90), retired (7.93 ± 6.07), and students (7.10 ± 6.31) (P = 9.82E-23). Except for those with disease course ≥20 years, DLQI scores increased gradually with prolongation of the disease course (P = 4.72E-22). The higher the severity of psoriasis, the higher the average DLQI score (P = 3.79E-113). The presence of psoriatic lesions at the exposed sites significantly affected DLQI scores (P <0.001). The average DLQI scores were significantly higher among individuals with nail holes, joint pain, and comorbidities than among those without these conditions (P <0.05). Correlation analysis indicated that the PASI scores were positively correlated with the DLQI scores (r = 0.26, P = 4.19E-134). Multinomial logistic regression analysis showed significant influencing factors (excluding comorbidity) with different degrees of impact based on the DLQI score (P <0.05).ConclusionPhysicians should focus on significant factors, such as sex, age, marital status, education, work status, sub-types, disease course, PASI score, without joint pain, and without nail holes, to improve the QoL of patients with psoriasis.Weiterlesen

BackgroundPsoriasis is associated with increased psychiatric comorbidity, yet patterns of mental health care use and spending remain unclear.ObjectiveTo characterize use and expenditures for outpatient mental health services and psychotropic medications among U.S. persons with psoriasis and identify sociodemographic disparities.MethodsCross-sectional analysis of 2,123 participants with psoriasis in the 2005-2022 Medical Expenditure Panel Survey. Negative binomial and two-part models examined associations between sociodemographic characteristics and mental health care utilization and spending.ResultsHigher education and income levels were associated with fewer psychiatrist visits, but lower-income groups had greater utilization overall. Men spent more on psychotropic medications than women. Racial minorities had lower medication spending than White patients. Medicare coverage was linked to greater total expenditure compared to private insurance.LimitationsPsoriasis severity was unavailable. International Classification of Diseases-based identification may undercount cases.ConclusionSubstantial sociodemographic and insurance disparities persist in mental health care use and spending among psoriasis patients.Weiterlesen

BackgroundPsoriasis is a frequent and complex dermatosis of uncertain origin. A few years ago, a family of gasdermin proteins was implicated in psoriasis pathogenesis. Although the number of therapeutic options for psoriasis is growing, considering the burden of the disease, treatment personalization, and the possibility of side effects or loss of the drug's efficacy, it is important to seek new therapeutic targets.ObjectiveThe aim of this study was to assess the efficacy of antibodies against gasdermin E (GSDME) in the treatment of psoriatic lesions.MethodsThe study involved 30 male BALB/c mice, 8 weeks old. 5% imiquimod cream was applied topically on the skin to induce psoriatic lesions. The next day after the psoriatic lesions appeared, the antibodies were administered. Mice from the study group received the rabbit polyclonal anti-GSDME antibody intravenously or intraperitoneally. The control group was administered sterile 0.9% saline solution.ResultsThe injection of anti-GSDME antibodies to mice with imiquimod-induced psoriasis resulted in the resolution of skin lesions, whereas the injection of saline to the control group did not result in significant changes.ConclusionAntibodies targeting GSDME seem to be promising therapeutic agents in psoriasis; however, their utility has to be confirmed in future studies.Weiterlesen

PurposeTo explore the mechanism of cuprotosis in psoriasis, screen cuprotosis related genes (PDCRGs) in psoriasis, and provide new targets for precise diagnosis and treatment of psoriasis.Material and methodsIntegrate bioinformatics analysis and experimental validation. Firstly, based on the GEO database (GSE161683, GSE166388, GSE277173), differentially expressed genes (DEGs) and weighted gene co-expression network analysis (WGCNA) in psoriasis were screened; Identification of differential cuprotosis related genes (PDCRGs) in psoriasis using a self built cuprotosis gene database (1098 CRGs); Screen key PDCRGs through PPI network, machine learning, and ROC analysis. Subsequently, a mouse model of psoriasis induced by imiquimod (IMQ) was constructed, and gene expression, copper ion levels, inflammatory factors, and oxidative stress factors were validated using qPCR, Western blot, immunohistochemistry, fluorescence, and ELISA.ResultsThirty-four PDCRGs were identified, among which STAT1, DLD, GBP1, CXCL10, PDHB, and LIAS are Hub genes. Machine learning and ROC analysis further identified APOL6, CD274, and LIAS as key diagnostic biomarkers. PDCRGs are significantly enriched in the TCA cycle, copper ion transport, and glucose metabolism pathways. The levels of FDX1 and serum copper ions were increased in the skin lesions of psoriasis mice, accompanied by upregulation of TCA cycle key proteins and PDCRGs expression; Copper overload triggers oxidative stress and inflammation cascade.ConclusionAPOL6, CD274, and LIAS were screened as cuprotosis markers in psoriasis. Overexpression of these PDCRGs in psoriasis model mice can promote copper ion accumulation and interfere with the TCA cycle, increase oxidative stress and inflammation levels, and ultimately lead to the occurrence of psoriasis. Therefore, targeted intervention of cuprotosis is of great significance for the clinical treatment of psoriasis.Weiterlesen

ObjectivesThe Disease Activity index for Psoriatic Arthritis (DAPSA) was developed to assess disease activity in patients with psoriatic arthritis (PsA). A modified version, DAPSA28, uses 28 joints instead of 66/68. This study evaluated key psychometric properties of DAPSA and DAPSA28.MethodsData from 1865 patients with PsA in the European Spondyloarthritis (EuroSpA) Research Collaboration Network, having DAPSA and DAPSA28 scores at baseline and follow-up, were analysed. Tests included assessment of internal construct validity by scree plots, confirmatory factor analysis (CFA) and structural equation modelling (SEM), supplemented by tests of differential item functioning (DIF) and evaluation of internal consistency reliability by Cronbach's α (CA). A subset of 625 patients was used for most analyses, except descriptive statistics, correlation matrix and CA.ResultsOne-dimensional CFA models for DAPSA and DAPSA28 showed acceptable model fit at baseline (root mean square error of approximation, RMSEA: 0.020, 0.034). However, model fit at 6 months follow-up was poor (RMSEA: 0.057, 0.063). SEM combining baseline and follow-up data could not identify an acceptable model fit. DIF was found for sex and country. CA indicated acceptable internal consistency (DAPSA: 0.65; DAPSA28: 0.63). Heterogeneity across countries was observed.ConclusionsOverall, the model fit was acceptable across model fit statistics, supporting internal construct validity, but some evidence of misfit at country level was disclosed. Our findings support acceptable internal consistency reliability, but DIF was found for sex and country. Based on mixed results of model fit and DIF, further investigation of these and other PsA disease activity measures is warranted.Weiterlesen

Cumulative life course impairment (CLCI) is the irreversible harm resulting from the chronic burden of disease, such as psoriasis. This cumulative impact encompasses physical, psychological, social, and emotional challenges that can significantly alter the life trajectory of a patient with psoriasis. The risk of CLCI and the impact of living with psoriasis are exacerbated when the disease is inadequately managed. Even with improvements in skin symptoms, psychological factors, such as anxiety about relapse, can persist, adding to the long-term burden. The development and validation of screening tools to better identify and assess CLCI may provide a valuable framework for clinical practice, supporting holistic care and serving as an effective measure for evaluating the long-term impact of new therapies.Weiterlesen

**DermatoVax – Eine App hilft beim Impfen** Eine neue App namens DermatoVax hilft Menschen mit Schuppenflechte (Psoriasis), sich impfen zu lassen.[1] Das ist wichtig, denn diese Menschen bekommen schneller Infektionen. Trotzdem impfen sich die meisten nicht ausreichend. Die App funktioniert einfach: Du gibst einige persönliche Daten ein, dann zeigt dir die App, welche Impfungen du brauchst.[1] Ärzte haben die App bewertet – das Ergebnis war sehr gut. Im Durchschnitt bekam sie 4,22 von 5 Punkten.[1] **Das beste Ergebnis:** 85 % der ärztlichen Tester denken, dass die App Menschen zum Impfen motiviert.[1] 89 % sind sicher, dass sie das Impfwissen verbessert.[1] Und 80 % glauben, dass sich Originaltitel: A Mobile App to Enhance Awareness of Vaccination in Adults With Psoriasis and Atopic Dermatitis: Development and Preliminary Evaluation Study. Link zur Quelle

Psoriasis-Arthritis tritt bei manchen Menschen erst nach dem 60. Lebensjahr auf[1]. Forscher wollten wissen, ob diese Spätzünder sich von Patienten mit früherem Krankheitsbeginn unterscheiden[1]. Sie untersuchten 281 Patienten. Bei 14 Prozent von ihnen war die Krankheit erst nach 60 ausgebrochen[1]. Was die Ärzte überraschte: Die älteren Patienten hatten weniger Beschwerden an den Sehnenansätzen[1]. Dafür zeigten sie aber deutlich mehr Herzprobleme[1]. Sie litten häufiger unter Fettstoffwechselstörungen[1]. Sie hatten auch mehr Herzinfarkte oder Schlaganfälle[1]. Das ist wichtig für Ärzte zu wissen. Ältere Menschen mit Psoriasis-Arthritis zeigen andere Symptome als jüngere[1]. Die Ärzte müssen deshalb besonders aufmerksam sein. Sie sollten auch das Herz dieser Patienten im Blick behalten[1]. Originaltitel: Late-onset psoriatic arthritis: data from a nationwide cross-sectional study Link zur Quelle

# Abnehmen hilft gegen Psoriasis Neue Studien zeigen es deutlich: Wenn du mit Psoriasis übergewichtig bist, kann abnehmen deine Haut deutlich verbessern.[1][2] Forschende haben mehrere Studien analysiert und sind zu einem klaren Ergebnis gekommen. Wer durch Diät oder Sport abnimmt, hat weniger Psoriasis-Beschwerden.[1] Die Verbesserung ist dabei nicht klein. Menschen, die ihr Gewicht reduzierten, erreichten häufiger eine starke Verbesserung ihrer Hauterscheinungen.[2] Das heißt: Ihre Psoriasis besserte sich um mindestens 50 bis 75 Prozent. Besonders interessant ist das für dich, wenn du übergewichtig oder adipös bist. Denn Übergewicht verstärkt Psoriasis-Entzündungen im Körper.[2] Wenn du abnimmst, bremst du diese Entzündungen. Die gute Nachricht lautet: Du brauchst keine Wunderdiät.[1] Normale Gewichtsverlust-Programme funktionieren. Das kann eine Ernährungsumstellung sein oder regelmäßig Sport treiben oder beides zusammen. Ärzte sollten daher Patienten mit Psoriasis und Übergewicht anbieten, beim Abnehmen zu helfen.[2] Das ist genauso wichtig wie Cremes oder Medikamente. Wenn du merkst, dass deine Psoriasis schwer ist, könnte ein Gespräch mit deinem Arzt über dein Gewicht sehr hilfreich sein. Originaltitel: Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis Link zur Quelle

# Wie Halsschmerzen zu Schuppenflechte führen können Forscher haben jetzt entdeckt, wie Psoriasis wirklich entsteht. Sie beobachteten, dass B-Zellen eine wichtige Rolle spielen. Diese B-Zellen wecken T-Zellen auf und lassen sie die Pigment-Zellen in der Haut angreifen. Das passiert besonders nach einer Mandelentzündung durch Streptokokken. Für Menschen, die das Erbe-Merkmal HLA-C*06:02 haben, ist das besonders problematisch. Bei ihnen verwechselt der Körper dann eigene Zellen mit Eindringlingen und greift sich selbst an. Die B-Zellen übernehmen dabei sozusagen die Rolle eines falschen Wachhundes. **Das erklärt auch, warum Psoriasis nach einer Halsentzündung oft ausbricht.** Manche Menschen bekommen Schuppenflechte-Schübe genau nach so einer Infektion. Jetzt weiß man endlich, warum das zusammenhängt. Die gute Nachricht: Diese Entdeckung könnte zu neuen Behandlungen führen. Ärzte könnten gezielter eingreifen, wenn sie verstehen, welche Zellen sich da gegenseitig hochfahren. Originaltitel: B Cells Can Trigger the T-Cell-Mediated Autoimmune Response Against Melanocytes in Psoriasis. Link zur Quelle

## Neuer Hoffnungsträger gegen Schuppenflechte: So wirkt Icotrokinra Icotrokinra ist ein neues Medikament zum Schlucken, das gegen mittelschwere bis schwere Schuppenflechte helfen soll.[1] Es funktioniert anders als viele bekannte Mittel: Der Wirkstoff blockiert gezielt den IL-23-Rezeptor in deinem Körper. Das ist wichtig, weil dieser Rezeptor die Entzündungen auslöst, die zu Schuppenflechte führen.[1] **Was die Studien zeigen** In den Studien FRONTIER-1 und FRONTIER-2 testeten Forscher das Mittel über 16 bis 52 Wochen. Die Ergebnisse sind beeindruckend: Schon nach vier Wochen begannen die entzündlichen Marker im Blut zu sinken. Noch besser: Diese Verbesserung hielt über das ganze Jahr an.[2] Das Besondere ist, dass höhere Dosen stärker wirken. Die höchste getestete Dosis (100 mg zweimal täglich) zeigte die besten Ergebnisse. Icotrokinra blockiert dabei sehr gezielt die IL-23-Entzündungen. Es beeinflusst andere Abwehrprozesse im Körper kaum – das könnte bedeuten, weniger Nebenwirkungen. **Was es für dich bedeutet** Nach 16 Wochen verschwanden die Symptome in der Haut deutlich. Die entzündlichen Proteine sanken sogar auf Werte normaler Haut. Das Fazit der Forscher: Das Mittel wirkt schnell und langfristig. Die gute Nachricht für dich: Es ist eine Tablette zum Einnehmen – kein Spritzen nötig.[1] Originaltitel: Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis. Link zur Quelle

IntroductionPsoriasis is a chronic inflammatory skin disease with a global prevalence of 1-5%, however its clinical and demographic profile in Kenya remains underexplored. This article describes the establishment of the Kenyan Psoriasis Registry at Moi Teaching and Referral Hospital in Eldoret, Kenya.Methods214 subjects were enrolled between October 2024 and August 2025 at Moi Teaching and Referral Hospital. Both healthy controls and patients with psoriasis completed enrollment surveys and physical exams, and donated saliva samples.ResultsThe initial cohort of 214 subjects (108 patients with psoriasis, 106 healthy controls) provides valuable insights into the demographics, clinical profiles, quality of life, and mental health characteristics of patients with psoriasis in Kenya. The mean age of psoriasis onset was 30.4 years, and mean age of diagnosis by a medical provider was 38.9 years old. 13.9% of patients with psoriasis reported a positive family history of psoriasis, and 9.3% of patients with psoriasis reported a diagnosis of psoriatic arthritis. The mean psoriasis area and severity index was 9.9 and mean Investigator Global assessment score was 3.0. Examination of treatment patterns revealed that moisturizers, prescription topical medications, and methotrexate were commonly tried while only 9.3% of individuals had ever received a biologic therapy. Patients with psoriasis reported significantly worse sleep disturbance, quality of life, and mental health compared to healthy controls.ConclusionThis data highlights the unique characteristics of patients with psoriasis in Kenya. The Kenyan Psoriasis Registry continues to enroll patients and conduct yearly follow-ups, aiming to deepen the understanding of psoriasis in this population. These findings underscore the need for targeted research and advocacy to improve psoriasis care in Kenya.Weiterlesen

This study aimed to evaluate the utility of netrin 1, CRP (C-reactive protein), and ESR (erythrocyte sedimentation rate) biomarkers for distinguishing between psoriatic arthritis (PsA) and psoriasis. This study included 44 patients with PsA and 44 with psoriasis. CASPAR (-Classification criteria for psoriatic arthritis) was used to classify PsA patients, and the PASI (-Psoriasis Area and Severity Index) was used to determine the degree of psoriatic plaques. Serum netrin 1 levels were measured using a commercial, ready-to-use ELISA kit that employs a quantitative immunoassay. Serum netrin 1 and ESR levels were similar between the PsA and psoriasis groups, but the median netrin 1 values were significantly higher in the PsA subtype with axial involvement than in the non-PsA subtype (respectively, 69.9 [64.0-97.6], 58.7 [56.2-64.0], p: 0.002). CRP levels were significantly higher in the PsA group than in the psoriasis group (B: - 0.134, OR [95% CI]: 0.874 [0.783-0.977], p: 0.018). A cut-off value of 12.05 for CRP was found to have a specificity of 27.3% and a sensitivity of 97.7% in distinguishing patients with PsA from those with psoriasis (AUC [95% CI]: 0.699 [0.590-0.809], p: 0.01). Netrin 1 is not a significant biomarker for distinguishing PsA from psoriasis, but it may be a potential biomarker for identifying the PsA subtype with axial involvement. Although CRP is a sensitive biomarker for distinguishing PsA from psoriasis, its specificity is low.Weiterlesen

BackgroundThe relationship between cancer and the use of systemic immunosuppressants in psoriasis treatment has not well established. The aim of this study was to evaluate the association between the systemic immunosuppressants used in the treatment for psoriasis and the risk of certain cancers in Korean patients with moderate to severe psoriasis.MethodsA retrospective cohort study was conducted involving 93,152 patients with moderate to severe psoriasis and 205,850 matched controls in Korea, using merged data from the National Health Insurance System, Health Insurance Review & Assessment Service, and Korea National Cancer Incidence Database from 2008 to 2018.ResultsThe study observed a lower incidence of any cancer in moderate to severe psoriasis patients (2.4%) compared to the general population (2.99%). However, there was a higher risk of hematologic cancers, particularly Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, and cutaneous T cell lymphoma. Notably, methotrexate doses of ≥ 17.5 mg/week increased the risk of hematologic cancer risk by 7.546 times and cutaneous T cell lymphoma risk by 9.038 times, but cyclosporine and corticosteroids use did not show a significant association with increased incidence of hematologic cancers. Meanwhile, use of cyclosporine, methotrexate and corticosteroid did not significantly affect the risk of skin cancer among patients with psoriasis.ConclusionThis study reveals an increased risk of hematologic cancers, such as cutaneous T cell lymphomas, associated with high-dose immunosuppressant use in moderate to severe psoriasis, underscoring the need for careful treatment management.Weiterlesen

BackgroundLife's Crucial 9 (LC9) is a new tool used to evaluate cardiovascular health. At present, no studies have reported the association between LC9 and psoriasis.MethodsThis cross-sectional study utilized data from the National Health and Nutrition Examination Survey (NHANES) conducted between 2009 and 2014. The LC9 score was calculated based on the American Heart Association's recommendations and the Patient Health Questionnaire-9 assessment. Psoriasis status was identified using self-reported questionnaires. Weighted multivariable logistic regression and restricted cubic splines were applied to assess the association between LC9 and psoriasis. Subgroup analyses were conducted for each covariate, and the interaction between LC9 and potential confounders was examined. Additionally, sensitivity analyses were performed to assess the robustness of the results.ResultsA total of 11,762 participants aged 20 years and older were included in this study. After comprehensive adjustments, a negative linear association was observed between psoriasis and LC9: Each 10-point increment in LC9 corresponded to an odds ratio (OR) of 0.87 (95% CI: 0.78-0.96) for psoriasis. Relative to participants in the lowest LC9 quartile (Q1), the ORs for psoriasis were 0.73 (95% CI: 0.55-0.96) for Q3 and 0.55 (95% CI: 0.36-0.85) for Q4. Among participants aged 45 to 64 years, those in the highest LC9 quartile (Q4) had an adjusted OR of 0.42 (95% CI: 0.23-0.78). Heavy drinkers in Q4 exhibited an adjusted OR of 0.37 (95% CI: 0.15-0.92). Sensitivity analyses confirmed these results.ConclusionA linear negative relationship between psoriasis and LC9 was identified in this study. This observational result suggesting that enhancing LC9-related cardiovascular health factors may serve as an effective approach for psoriasis prevention and management.Weiterlesen

ObjectiveThe purpose of this study was to evaluate the relationship between nutritional status-assessed by the Controlling Nutritional Status (CONUT) score-and disease activity, fatigue, and sleep quality in patients with psoriatic arthritis (PsA), with attention to sex-specific differences.Methods113 adults with PsA were included in this cross-sectional study. Nutritional status was classified as normal (CONUT 0-1) or malnutrition (CONUT ≥ 2). Disease activity was assessed using the Disease Activity in Psoriatic Arthritis (DAPSA) score, fatigue using the Fatigue Severity Scale (FSS), and sleep quality using the Jenkins Sleep Scale (JSS). Correlation and ROC analyses were performed.ResultsMalnutrition was identified in 18.6% of patients. Compared to those with normal nutritional status, malnourished patients had higher CRP (12.8 vs. 6.4 mg/L, p = 0.012) and lower albumin and lymphocyte levels (p < 0.001). High disease activity (DAPSA > 28) was more common in the malnutrition group (38.1% vs. 15.2%, p = 0.029). The CONUT score correlated with DAPSA (Rho = 0.327, p < 0.001), CRP (Rho = 0.422, p < 0.001), and fatigue severity (Rho = 0.186, p = 0.048). No association was observed with sleep quality. ROC analysis showed that CONUT ≥ 2 predicted high disease activity (AUC 0.70). In sex-stratified analyses, correlations with DAPSA and fatigue were present only in females.ConclusionHigher CONUT scores were associated with greater disease activity and fatigue among patients with psoriatic arthritis. These results underscore the potential value of incorporating routine nutritional evaluation into the comprehensive management of PsA.Weiterlesen